Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

The management of chronic thromboembolic pulmonary hypertension has significantly changed over the last decade with the availability of both specific therapies and interventional treatments. In parallel, implantable pumps for intravenous administration of treprostinil have broadened the spectrum of...

Descripció completa

Dades bibliogràfiques
Autors principals:	Regina Steringer-Mascherbauer, Charlotte Huber, Uwe Fröschl, Dagmar Engleder, Reinhold Függer, Maria Lummersdorfer, Ralf Lenhard, Martin Martinek
Format:	Article
Idioma:	English
Publicat:	MDPI AG 2023-07-01
Col·lecció:	Journal of Cardiovascular Development and Disease
Matèries:	chronic thromboembolic pulmonary hypertension implantable pump intravenous treprostinil
Accés en línia:	https://www.mdpi.com/2308-3425/10/8/318

Ítems similars

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
per: Pavel Jansa, et al.
Publicat: (2023-07-01)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
per: Regina Steringer-Mascherbauer, et al.
Publicat: (2020-11-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
per: John W. Swisher, PhD, MD, et al.
Publicat: (2017-01-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
per: Jan C. Kamp, et al.
Publicat: (2021-05-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
per: Marcin Kurzyna, et al.
Publicat: (2017-12-01)

Venoarterial extracorporeal membrane oxygenation for vasoplegic shock after treprostinil refill of an implanted intravenous pump: a case report
per: Lucía Valencia, et al.
Publicat: (2024-01-01)

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure
per: Xiaofeng Wang, et al.
Publicat: (2024-10-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
per: Julia McSweeney, et al.
Publicat: (2023-04-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
per: Lianghua Xiao, et al.
Publicat: (2024-09-01)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
per: Ibrahim Alissa, et al.
Publicat: (2023-04-01)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
per: Felix Rafael De Bie, et al.
Publicat: (2022-07-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
per: Piotr Kędzierski, et al.
Publicat: (2025-01-01)

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study
per: Enhuan Wei, et al.
Publicat: (2023-11-01)

Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
per: Daniel Lachant, DO, et al.
Publicat: (2025-05-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
per: Nicholas S. Hill, et al.
Publicat: (2022-07-01)

Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function
per: Aleksandra Judina, et al.
Publicat: (2023-12-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
per: Aparna C. Swaminathan, et al.
Publicat: (2024-11-01)

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
per: Leslie A. Spikes, et al.
Publicat: (2022-04-01)

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
per: Helena Gauani, et al.
Publicat: (2022-04-01)

Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report
per: Jacqueline Brewer, et al.
Publicat: (2023-06-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
per: Shelsey W. Johnson, et al.
Publicat: (2022-07-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
per: Garance Kopp, et al.
Publicat: (2020-10-01)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
per: Helena Gauani, et al.
Publicat: (2023-03-01)

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy
per: Donna Steinbacher, et al.
Publicat: (2024-04-01)

Renal infarction associated with low dose intravenous immunoglobulin in a kidney transplant recipient with sepsis: a case report and literature review
per: Eun Woo Choi, et al.
Publicat: (2021-10-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
per: N. V. Marukyan, et al.
Publicat: (2021-05-01)

Balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
per: N M Danilov, et al.
Publicat: (2019-04-01)

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review
per: Burger CD, et al.
Publicat: (2024-05-01)

Direct prostacyclin transition in pediatric patients with pulmonary hypertension
per: Kelly Merrill, et al.
Publicat: (2024-04-01)

Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
per: Cheng Hong, et al.
Publicat: (2022-05-01)

Efficacy and safety of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension
per: Zheng-Wei Chen, et al.
Publicat: (2021-03-01)

Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation
per: Gil Bu Kang, et al.
Publicat: (2023-11-01)

Inoperable chronic thromboembolic pulmonary hypertension: Evolution of prognosis over 10 years of new emerging therapies
per: Diederik P. Staal, et al.
Publicat: (2024-07-01)

Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension
per: Chen TX, et al.
Publicat: (2018-01-01)

Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty
per: Qi Jin, et al.
Publicat: (2019-11-01)

Chronic Thromboembolic Pulmonary Hypertension and ChronicThromboembolic Pulmonary Disease
per: HUANG Shenshen, et al.
Publicat: (2023-01-01)

Congruency between clinician‐assessed risk and calculated risk of 1‐year mortality in patients with pulmonary arterial hypertension: A retrospective chart review
per: Amresh Raina, et al.
Publicat: (2024-10-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
per: Jenna M. Faircloth, et al.
Publicat: (2023-08-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
per: Jenna M. Faircloth, et al.
Publicat: (2023-03-01)

Perioperative thromboembolism prophylaxis in children – is it necessary?
per: Izabela Pągowska-Klimek
Publicat: (2020-08-01)